BioSpace News Archive

Transcenta Holding Limited announces that the preclinical anti-tumor efficacy and safety results of [177Lu]Lu-TST001 have been published on European Journal of Nuclear Medicine and Molecular Imaging.

Medivir AB announced that it has signed an agreement with Lonza for the manufacture of a new GMP campaign of fostrox drug substance for the planned phase 2b to enable study drug availability end of 2024 and ensure maximum momentum in the fostrox development program.

Following its successful fundraising of C$4.91 million, Canadian life sciences company Ondine Biomedical Inc. will continue accelerating commercialisation of its proven nasal photodisinfection technology.

TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that it will change its ratio of its American Depositary Shares to ordinary shares from one ADS representing one ordinary share to one ADS representing twenty ordinary shares.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).

Pfizer Inc. provided its full-year 2024 guidance, which includes the expected financial impact from the Seagen transaction.

EvolveImmune Therapeutics provided a corporate and program update related to the advancement of its pipeline of first-in-category precision immuno-oncology agents.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, is pleased to be a sponsor of the second annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) that is being held in Paris, France from December 13-15.

Neutron Therapeutics, a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced that its compact accelerator has received final acceptance for use at the University of Birmingham’s High Flux Accelerator-Driven Neutron Facility.

Aesyra, a medical device company pioneering oral appliance technologies to improve sleep, announced it has raised $3 million in seed financing.